P3.12.40 Safety and Patient-Reported Outcomes With Tepotinib in Patients With METex14 Skipping NSCLC: =3-Years Follow-Up of VISION
Year: 2025
Type: article
Source: Journal of Thoracic Oncology
Institutions: Vall d'Hebron Institute of Oncology, Vita-Salute San Raffaele University, Fondazione IRCCS Istituto Nazionale dei Tumori, Centre Hospitalier Universitaire de Bordeaux, The University of Texas MD Anderson Cancer Center, Leiden University Medical Center, Université Toulouse III - Paul Sabatier, Centre Hospitalier Universitaire de Toulouse, Centre National de la Recherche Scientifique, Inserm, Université de Lille, Institut Pasteur de Lille, Centre Hospitalier Universitaire de Lille, Centre de Recherches en Cancérologie de Lille, Antwerp University Hospital, German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, National Center for Tumor Diseases, German Center for Lung Research, Asklepios Fachkliniken München-Gauting, National Taiwan University, National Taiwan University Hospital, Samsung Medical Center, Sungkyunkwan University, Peking University Cancer Hospital, Carl von Ossietzky Universität Oldenburg, Pius Hospital Oldenburg, Instituto Oncológico Dr. Rosell, Hospital Universitario Dexeus, Merck B.V. (Netherlands), Merck Healthcare KGaA, Darmstadt (Germany), Merck KGaA, Darmstadt (Germany), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415520033